Skip to main content
Log in

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To estimate the cost effectiveness (from the UK NHS and personal social service perspectives) of infliximab plus methotrexate (MTX) compared with MTX alone, in the treatment of patients with severe rheumatoid arthritis (RA) who were not adequately controlled on disease-modifying antirheumatic drugs and who were resistant to MTX.

Method: Clinical data for the first year of therapy were taken from the ATTRACT (Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy) and a Markov model developed to assess costs and consequences in the longer term. Transition probabilities and health state valuations for the model were estimated based on the ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) cohort, and resource use and costs (£, 2000 values) obtained from various sources in the UK. Univariate sensitivity analyses were conducted to test the robustness of the results.

Results: The primary analysis suggested that infliximab plus MTX had an ICER of £33 618 per QALY gained. Alternative modelling assumptions and various other sensitivity analyses were applied, but the ICER always remained within the range for interventions typically funded by the NHS.

Conclusion: This model suggests, with its underlying assumptions and data, that the combination of infliximab and MTX may be a cost-effective treatment (from the UK NHS and personal social service perspectives) for patients experiencing RA that cannot be maintained on MTX alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table XI
Table X

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11

    Article  PubMed  CAS  Google Scholar 

  2. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28–33

    Article  PubMed  CAS  Google Scholar 

  3. Gabriel SE, Crowson CS, Campion ME, et al. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24: 43–8

    PubMed  CAS  Google Scholar 

  4. Meenan RE Yelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: a patient oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 827–33

    Article  PubMed  CAS  Google Scholar 

  5. Spitz PW. The medical, personal, and social costs of rheumatoid arthritis. Nuts Clin North Am 1984; 19: 575–82

    CAS  Google Scholar 

  6. Lubeck DP, Spitz PW, Fries IF, et al. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29: 488–93

    Article  PubMed  CAS  Google Scholar 

  7. Jacobs J, Keinheksel JA, Britton M, et al. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988; 41: 215–23

    Article  PubMed  CAS  Google Scholar 

  8. Yelin E. The costs of rheumatoid arthritis: absolute, incremental and marginal estimates. J Rheumatol 1996; 23: 47–51

    Google Scholar 

  9. Lanes SF, Lanza LL, Redensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in amanaged care setting: the importance of drug and surgery costs. Arthritis Rheum 1997; 40: 1475–81

    Article  PubMed  CAS  Google Scholar 

  10. Clarke AE, Zowall H, Levington C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 1051–60

    PubMed  CAS  Google Scholar 

  11. van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, et al. Direct cost of rheumatoid arthritis during the first six years: a cost-ofillness study. Br J Rheumatol 1998; 37: 837–47

    Article  PubMed  Google Scholar 

  12. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56

    Article  PubMed  CAS  Google Scholar 

  13. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602

    Article  PubMed  CAS  Google Scholar 

  14. Maim R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9

    Article  Google Scholar 

  15. Wong JB, Gurkipal S, Kavanaugh A. Estimating the costeffectiveness of 54 weeks of Infliximab for rheumatoid arthritis. Am J Med 2002; 113: 400–8

    Article  PubMed  Google Scholar 

  16. Wong JB, Wong CJ, Hazes JM, et al. Clinical significance of rapid radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2001; 6 (1): 130–1

    Google Scholar 

  17. Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1480–8

    PubMed  CAS  Google Scholar 

  18. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781–90

    Article  PubMed  CAS  Google Scholar 

  19. British Medical Association. The British National Formulary of pharmaceutical products [online]. 2000. Available from URL: http://www.bnf.org [Accessed 2000 Dec 1]

  20. NICE (The National Institute for Clinical Excellence). Guidance for manufacturers and sponsors. Technology Appraisals Process Series 5 [online]. Available from URL: http://www.nice.org.uk [Accessed 2002 Feb 1]

  21. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis: I. Clinical features and diagnosis. BMJ 1995; 310: 587–90

    CAS  Google Scholar 

  22. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2746–9

    Article  PubMed  CAS  Google Scholar 

  23. Raftery J. NICE: faster access to modern treatment? Analysis of guidance on health technologies. BMJ 2001; 323: 1300–3

    Article  PubMed  CAS  Google Scholar 

  24. van Riel PL, van Gestel AM, van de Putte LB. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 40–2

    PubMed  Google Scholar 

  25. Wijnands MJ, van’t Hof MA, van Leeuwen MA, et al. Longterm second-line treatment: a prospective drug survival study. Br J Rheumatol 1992; 31: 253–8

    Article  PubMed  CAS  Google Scholar 

  26. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35: 138–45

    Article  PubMed  CAS  Google Scholar 

  27. Weinblatt ME. Methotrexate in rheumatoid arthritis. Bull Rheum Dis 1993; 42: 4–7

    PubMed  CAS  Google Scholar 

  28. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2751–61

    Article  PubMed  CAS  Google Scholar 

  29. Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003; 42: 326–35

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Marco Barbieri received a research fellowship from Schering-Plough Inc. (at the Centre for Health Economics). Professor Drummond has received consultancy payments and grant funding from Schering-Plough Inc. Professor Wong has received grant funding and speaking honoraria from Schering-Plough Inc. and Centocor. This work was conducted whilst Marco Barbieri was a research fellow in the Centre for Health Economics, University of York.

Marco Barbieri was involved in the data collection for adapting the model to the UK setting and in writing the manuscript. John Wong was involved in building and populating the decision model, running the analyses and preparation of the manuscript. Michael Drummond was mainly involved in the preparation of the manuscript.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbieri, M., Wong, J.B. & Drummond, M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 23, 607–618 (2005). https://doi.org/10.2165/00019053-200523060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200523060-00007

Keywords

Navigation